Julia G Butchko - Chief Dev. & Tech. Officer, Immunovant, Inc

As of September 14, 2021


Julia G Butchko Net Worth

  • Net worth is estimated to be at least $415.51K
  • Owns at least 5,000 units of Immunovant, Inc stock

Julia G Butchko Compensation at Immunovant, Inc in 2020

  • Earned a $372,000 salary and a $148 bonus
  • Rewarded $926,500 in stock value and options
  • Received a total compensation of $7,842,357

Julia G Butchko Trading

  • Largest purchase of shares was 5,000 units , worth over $190.85K on September 15, 2020
  • In total has made about 6 transactions over 2 years
  • Usually trades in September, with the busiest year in 2021
Ticker
Type
Value
Price per Share
Shares
Filing Date
No matching records found
1

Julia G Butchko Mailing Address

  • Mailing address is 320 W 37th Street, 3rd Floor New York NY 10016 NY

Immunovant, Inc Executive Compensation

Name
Year
Salary
Bonus
Stock Awards
Option Awards
Other Earnings Plans or Compensations
Other Compensation
Total
Peter Salzmann, M.D., M.B.A. 2020 $ 567,000 $ 311,850 $ 3,252,500 $ 11,104,950 $ $ 139,004 $ 15,375,304
Peter Salzmann, M.D., M.B.A. 2019 $361,010 $500,000 - $7,721,344 $224,480 - $8,806,834
Pamela Yanchik Connealy, M.B.A. 2020 $393,000 $157,200 $785,400 $4,258,363 - $8,742 $5,602,705
Pamela Yanchik Connealy, M.B.A. 2019 $147,618 - - $2,437,762 $61,233 $129,321 $2,775,934
Julia G. Butchko, Ph.D. 2020 $372,000 $148,800 $926,500 $6,384,856 - $10,201 $7,842,357
Michael J. Elliott, 2020 $242,425 $96,000 $1,659,200 $14,229,311 - $9,695 $16,236,631
Rita Jain, M.D. 2020 $101,137 $38,526 $2,703,005 $10,666,997 - $3,319 $13,512,984
No matching records found

Source: https://www.sec.gov/Archives/edgar/data/1764013/000176401321000083/imvt-20210331defproxy.htm

Immunovant, Inc Insider Trading

  • The most recent transaction was 18,247 units bought on August 30, 2021 by Douglas J Hughes worth over $150.36K
  • In the last year, insiders at Immunovant, Inc bought an estimated value of $397.22M
  • The most active traders are Julia G Butchko, Chief Dev. & Tech. Officer,  Roivant Sciences Ltd,  and Peter Salzmann, Chief Executive Officer
  • Insider trading is most common in December, with the busiest year in 2021

Immunovant, Inc. Insider Trades

Insider Names
Type
Value
Price per Share
Shares
Filing Date
No matching records found
1